The bispecific antibody therapeutics market is projected to grow at an annualized rate of ~16%, in the span of 2019 to 2030

Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Sponsored Link Spot Available — Get This Spot Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/286/request-sample.html

Key Market Insights
 With two approved drugs and close to 300 clinical / preclinical product candidates, the bispecific antibody therapeutics pipeline has evolved significantly over the past few years
 The pipeline features drug candidates that target a wide range of biological antigens based on different antibody formats through novel mechanisms of action; more than 50% of these act by retargeting or activation of T-Cells
 To gain a competitive edge in the market, developers are actively exploring novel biological targets and mechanisms of action to treat diverse disease indications
 Although start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also actively engaged
 In order to cater to the evolving needs of developers, technology providers have established presence across different regions; the US and EU have emerged as the key hubs
 Close to 50,000 patients were estimated to have been enrolled in clinical trials evaluating bispecific antibody therapeutics, across various geographical locations and phases of development
 The increasing interest of stakeholders in this domain can also be gauged by the rising product development / commercialization, R&D and technology licensing deals being signed across various regions
 Given the complexities associated with the development of bispecific antibodies, contract organizations have become an indispensable part of the development and manufacturing process of antibody therapeutics
 In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products

For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]
Contact Email
[email protected]
Issued By
Roots Analysis
Country
United States
Categories
Biotech
Last Updated
March 5, 2021

Disclaimer: This press release was submitted by a registered PRBASE contributor and has not been verified or endorsed by PRBASE. PRBASE assumes no responsibility or liability for its accuracy, content, legality, or reliability. The contact email for this release can be viewed here. See our Disclaimer.

Delete Press Release · Edit Press Release